Lexicon showed mice ate less when taking LX9851 and semaglutide than when on either molecule as a single agent. As importantly for Lexicon’s positioning of LX9851 in chronic weight management ...

Researchers found that semaglutide reduced inflammation in the brains of genetically modified mice that mimic Alzheimer’s disease and improved their memory performance. The findings, published ...

Mice treated with semaglutide ate less and exhibited low VTA DA neuron activity; however, artificially activated neurons during food consumption overcame the appetite-reducing effect of ...

RedHill Biopharma (RDHL) announced the new publication of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an ...

Semaglutide can cause thyroid cancer in rats and mice. It is unknown whether the drug can cause thyroid cancer in humans. Due to the possible risk, doctors typically will not prescribe Ozempic or ...

ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

In new research, experts investigated the link between semaglutide use and muscle loss. To do this, they fed male mice a high-fat, high-sugar diet over a number of weeks before switching their ...

For years, it’s been linked to weight loss — and a new study published in the journal Nutrients in February found that it makes the body behave similarly to how it does on semaglutide drugs ...

Breaking bread is a powerful act of connection and shared moments, transcending barriers and bridging gaps. As we break bread we promote friendship, trust, and a sense of belonging.

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation ... discovery that knockout mice lacking the target ...